Prediction Case File
YouTubeEvaluation Complete

Ranking Every Big Tech Stock: Best to Worst

5 extracted signals · 5 resolved · 0 still active

The Patient Investor profile imageThe Patient InvestorIndependent analyst profile
Source published
29 Aug 2026, 16:52 UTC
Recorded by Tahlil Plus
29 Aug 2026, 19:46 UTC
Video preview for Ranking Every Big Tech Stock: Best to Worst
Source overview

AI-generated source summary

The analysis covers several major tech stocks, focusing on their current valuations and recent performance. Broadcom (AVGO) is seen as a buy with a target of $400, based on strong earnings growth and a favorable forward PE ratio. Apple (AAPL) is rated similarly, with growth expectations and a target of $350. Amazon (AMZN) is also in the buy category, with its stock at $266.43 and a target of $300, driven by strong operational performance in logistics and robotics. NVIDIA (NVDA) is noted to be down 4.57% recently but is expected to show strong growth, with a target of $240, although the analyst places it in the 'wait' category due to high valuation multiples. Google (GOOGL) is considered overvalued with a stock price of $342.88, and the analyst is looking for a pullback to $265, placing it in the 'avoid' category for now due to its high P/E ratio.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Evaluation Complete
Signals
5
Extracted from this source
Open
0
Still being tracked
Successful
0
Resolved successfully
Failed
5
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
0%
5 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  3. Market predictions extracted

    5 eligible signals linked to this case.

  4. Source processing completed

    Source analysis and structured extraction completed.

  5. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

  6. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  7. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

Analyst snapshot

The Patient Investor

Platform-wide history, separate from this source evaluation.

Reliability
47.2
Tracked signals
327
Historical success
33.8%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail